Company Filing History:
Years Active: 2020
Title: Subha Madhavan: Innovator in Systems Medicine for Personalized Oncology
Introduction
Subha Madhavan is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of personalized oncology through his innovative work in systems medicine. His research focuses on integrating patient characteristics with high-throughput research data to enhance cancer treatment.
Latest Patents
Subha Madhavan holds 1 patent for a "Systems medicine platform for personalized oncology." This invention is directed towards a web-based platform that facilitates both basic and clinical research activities. It integrates patient characteristics and clinical outcome data with various high-throughput research data in a unified environment. The platform addresses the limitations of existing data repositories, which often focus on a single data type and lack support for integration across multiple technologies. The invention includes a comprehensive collection of bioinformatics and systems biology tools for the analysis and visualization of four major 'omics' types: DNA, mRNA, microRNA, and metabolites, as well as next-generation sequencing. This innovative platform aids in the identification of trends and patterns in integrated datasets, ultimately facilitating the use of better-targeted therapies for cancer.
Career Highlights
Subha Madhavan is affiliated with Georgetown University, where he continues to advance research in personalized medicine. His work has garnered attention for its potential to revolutionize cancer treatment by providing a more holistic view of patient data.
Collaborations
Some of his notable coworkers include Michael A Harris and Yuriy Gusev, who contribute to the collaborative efforts in research and development within the field of systems medicine.
Conclusion
Subha Madhavan's innovative contributions to personalized oncology through his systems medicine platform exemplify the potential of integrating diverse data types to improve cancer therapies. His work at Georgetown University continues to pave the way for advancements in targeted cancer treatment.